Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: A frequentist meta-analysis approach

Research output: Contribution to journalArticle

Abstract

This meta-analysis assesses the efficacy and safety of triple therapy with either boceprevir or telaprevir compared to the standard of care (SoC), pegylated interferon plus ribavirin, in patients chronically infected with genotype 1 hepatitis C virus (HCV). We included 10 randomized controlled trials comprising 33 individual treatment arms which enrolled 5,312 subjects. Meta-analysis for sustained virologic response (SVR) provided evidence that triple therapy with either boceprevir or telaprevir increased response by 1.76 times (CI-95% 1.63-1.89) in comparison with SoC. However, heterogeneity was strong (I-2 79.7% p for heterogeneity

Original languageEnglish
Pages (from-to)263-276
Number of pages14
JournalNew Microbiologica
Volume37
Issue number3
Publication statusPublished - 2014

Keywords

  • Adverse event
  • Boceprevir
  • Direct-acting antiviral compounds
  • Experienced patients
  • Hepatitis C infection
  • Iatrogenic disease
  • Naïve patients
  • Opportunistic infection
  • Sustained virological response
  • Telaprevir

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Triple therapy for hepatitis C improves viral response but also increases the risk of severe infections and anaemia: A frequentist meta-analysis approach'. Together they form a unique fingerprint.

  • Cite this